Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BLFSNASDAQ:ESTANASDAQ:MDXGNASDAQ:SMTI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLFSBioLife Solutions$23.71+10.3%$22.58$18.70▼$29.55$1.13B1.82396,618 shs866,546 shsESTAEstablishment Labs$38.00-0.1%$33.51$26.56▼$52.41$1.10B0.74473,723 shs237,757 shsMDXGMiMedx Group$6.49+2.4%$6.83$5.47▼$10.14$958.59M1.82687,759 shs372,385 shsSMTISanara MedTech$29.49+2.1%$30.36$25.86▼$39.08$262.11M1.3826,762 shs29,904 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLFSBioLife Solutions+10.28%+8.61%+11.11%-8.21%+10.07%ESTAEstablishment Labs-0.05%+9.70%+14.22%-8.87%-29.49%MDXGMiMedx Group+2.37%+0.31%-6.93%-17.74%-12.18%SMTISanara MedTech+2.11%+3.80%-7.38%-10.66%+5.89%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBLFSBioLife Solutions1.8794 of 5 stars3.51.00.00.01.22.50.6ESTAEstablishment Labs2.7351 of 5 stars3.43.00.00.02.52.50.6MDXGMiMedx Group3.7235 of 5 stars3.52.00.00.03.73.31.9SMTISanara MedTech2.7401 of 5 stars3.53.00.00.03.01.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBLFSBioLife Solutions 3.00Buy$31.1731.45% UpsideESTAEstablishment Labs 2.80Moderate Buy$52.4037.89% UpsideMDXGMiMedx Group 3.00Buy$12.5092.60% UpsideSMTISanara MedTech 3.00Buy$49.5067.85% UpsideCurrent Analyst Ratings BreakdownLatest SMTI, ESTA, BLFS, and MDXG Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/16/2025ESTAEstablishment LabsBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy ➝ Buy$62.005/15/2025SMTISanara MedTechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$51.00 ➝ $53.005/14/2025ESTAEstablishment LabsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$48.005/13/2025BLFSBioLife SolutionsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.004/14/2025ESTAEstablishment LabsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageHold3/26/2025SMTISanara MedTechCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$46.00 ➝ $46.003/26/2025SMTISanara MedTechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$50.00 ➝ $51.00(Data available from 6/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBLFSBioLife Solutions$87.76M12.83N/AN/A$7.67 per share3.09ESTAEstablishment Labs$170.24M6.45N/AN/A$0.71 per share53.52MDXGMiMedx Group$352.38M2.72$0.16 per share41.75$0.98 per share6.62SMTISanara MedTech$91.57M2.86N/AN/A$5.22 per share5.65Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBLFSBioLife Solutions-$66.43M-$0.29N/AN/AN/A-38.98%-6.61%-5.54%8/14/2025 (Estimated)ESTAEstablishment Labs-$78.50M-$3.10N/AN/AN/A-46.13%-184.55%-24.81%8/5/2025 (Estimated)MDXGMiMedx Group$58.23M$0.2711.8020.28N/A23.86%26.21%18.15%7/30/2025 (Estimated)SMTISanara MedTech-$4.30M-$1.34N/AN/AN/A-10.71%-19.86%-10.91%8/11/2025 (Estimated)Latest SMTI, ESTA, BLFS, and MDXG EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025SMTISanara MedTech-$0.31-$0.41-$0.10-$0.41$23.48 million$23.43 million5/8/2025Q1 2025BLFSBioLife Solutions-$0.03$0.04+$0.07-$0.01$22.22 million$23.94 million5/7/2025Q1 2025ESTAEstablishment Labs-$0.83-$0.70+$0.13-$0.70$41.15 million$41.38 million4/30/2025Q1 2025MDXGMiMedx Group$0.06$0.06N/A$0.05$86.32 million$88.21 million3/25/2025Q4 2024SMTISanara MedTech-$0.19-$0.18+$0.01-$0.18$22.75 million$26.31 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBLFSBioLife SolutionsN/AN/AN/AN/AN/AESTAEstablishment LabsN/AN/AN/AN/AN/AMDXGMiMedx GroupN/AN/AN/AN/AN/ASMTISanara MedTechN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBLFSBioLife Solutions0.032.781.78ESTAEstablishment Labs5.943.622.29MDXGMiMedx Group0.104.103.53SMTISanara MedTech0.762.232.02Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBLFSBioLife Solutions93.24%ESTAEstablishment Labs72.91%MDXGMiMedx Group79.15%SMTISanara MedTech8.10%Insider OwnershipCompanyInsider OwnershipBLFSBioLife Solutions2.20%ESTAEstablishment Labs11.44%MDXGMiMedx Group1.70%SMTISanara MedTech54.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBLFSBioLife Solutions44047.50 million45.37 millionOptionableESTAEstablishment Labs96028.92 million24.80 millionOptionableMDXGMiMedx Group870147.70 million145.04 millionOptionableSMTISanara MedTech608.89 million4.01 millionNot OptionableSMTI, ESTA, BLFS, and MDXG HeadlinesRecent News About These CompaniesSanara MedTech Inc. (NASDAQ:SMTI) Short Interest Down 13.7% in MayJune 5 at 6:47 PM | marketbeat.comFY2025 EPS Estimate for Sanara MedTech Increased by AnalystMay 20, 2025 | marketbeat.comQ2 EPS Estimates for Sanara MedTech Reduced by HC WainwrightMay 20, 2025 | marketbeat.comDimensional Fund Advisors LP Has $529,000 Stock Holdings in Sanara MedTech Inc. (NASDAQ:SMTI)May 19, 2025 | marketbeat.comSanara MedTech Shares Down, Investors Sought For Pilot ProgramMay 15, 2025 | marketwatch.comEarnings call transcript: Sanara Medtech Q1 2025 earnings miss forecastsMay 15, 2025 | investing.comEarnings call transcript: Sanara Medtech Q1 2025 earnings miss forecastsMay 15, 2025 | investing.comSanara MedTech Inc (SMTI) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amid Rising ...May 15, 2025 | finance.yahoo.comSanara MedTech Inc (SMTI) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amid Rising ...May 15, 2025 | finance.yahoo.comSanara MedTech Inc. (NASDAQ:SMTI) Q1 2025 Earnings Call TranscriptMay 15, 2025 | msn.comSanara MedTech Inc. (NASDAQ:SMTI) Q1 2025 Earnings Call TranscriptMay 15, 2025 | msn.comSanara MedTech Inc. (SMTI) Q1 2025 Earnings Call TranscriptMay 14, 2025 | seekingalpha.comSanara MedTech Inc. (SMTI) Reports Q1 Loss, Tops Revenue EstimatesMay 14, 2025 | zacks.comSanara MedTech Inc. Reports First Quarter 2025 Financial Results (Unaudited)May 14, 2025 | gurufocus.comSanara MedTech Inc. Reports First Quarter 2025 Financial Results (Unaudited) | SMTI Stock NewsMay 14, 2025 | gurufocus.comSanara MedTech Inc. Reports First Quarter 2025 Financial Results (Unaudited)May 14, 2025 | investing.comSanara MedTech Inc. Reports First Quarter 2025 Financial Results (Unaudited)May 14, 2025 | globenewswire.comSanara MedTech (SMTI) Projected to Post Earnings on WednesdayMay 9, 2025 | marketbeat.comWith 31% ownership, Sanara MedTech Inc. (NASDAQ:SMTI) insiders have a lot riding on the company's futureMay 7, 2025 | uk.finance.yahoo.comSanara MedTech Inc. to Report Q1 2025 Financial Results on May 14, 2025April 23, 2025 | quiverquant.comSanara MedTech to Report First Quarter 2025 Financial Results on May 14, 2025April 23, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsIntel’s Turnaround May Be the Best Bet No One’s WatchingBy Jeffrey Neal Johnson | May 30, 2025View Intel’s Turnaround May Be the Best Bet No One’s WatchingAnalysts Think These Stocks Could More Than Double in ValueBy Nathan Reiff | May 23, 2025View Analysts Think These Stocks Could More Than Double in ValueSymbotic Gets Big Earnings Lift: Is the Stock Investable Again?By Leo Miller | May 16, 2025View Symbotic Gets Big Earnings Lift: Is the Stock Investable Again?SMTI, ESTA, BLFS, and MDXG Company DescriptionsBioLife Solutions NASDAQ:BLFS$23.71 +2.21 (+10.28%) Closing price 06/6/2025 04:00 PM EasternExtended Trading$23.73 +0.02 (+0.08%) As of 06/6/2025 06:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioLife Solutions, Inc. develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line that comprises of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides cryogenic freezer technology for controlled rate freezing and cryogenic storage of biologic materials; ultra-low temperature mechanical freezers; evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage and transport services. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.Establishment Labs NASDAQ:ESTA$38.00 -0.02 (-0.05%) Closing price 06/6/2025 04:00 PM EasternExtended Trading$38.02 +0.02 (+0.05%) As of 06/6/2025 04:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander. The company sells its products to physicians, hospitals, and clinics through distributors and direct sales force in Europe, the Middle East, Latin America, and Asia. Establishment Labs Holdings Inc. was incorporated in 2004 and is headquartered in Alajuela, Costa Rica.MiMedx Group NASDAQ:MDXG$6.49 +0.15 (+2.37%) Closing price 06/6/2025 04:00 PM EasternExtended Trading$6.31 -0.18 (-2.79%) As of 06/6/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a barrier membrane allograft used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; and EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications. The company's products have applications in the areas of wound care, burn, surgical sectors of healthcare. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. was founded in 2006 and is headquartered in Marietta, Georgia.Sanara MedTech NASDAQ:SMTI$29.49 +0.61 (+2.11%) Closing price 06/6/2025 04:00 PM EasternExtended Trading$29.55 +0.06 (+0.20%) As of 06/6/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. It also provides BIAKOS Antimicrobial Skin and Wound Cleanser, a patented product that contains synergistic ingredients that have been shown to impact mature biofilm microbes; BIAKOS Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing that helps against planktonic microbes, as well as immature and mature biofilms; and BIAKOS Antimicrobial Skin and Wound Irrigation Solution. In addition, it develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; TEXAGEN, a multi-layer amniotic membrane allograft used as an anatomical barrier with robust handling that can be sutured for securement; and VIM Amnion Matrix, a homologous wound covering product. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/02 - 06/06 This Banking Giant Just Got a $90 Price Target Upgrade Broadcom Slides on Solid Earnings, AI Outlook Still Strong The Market’s Silent Warning: What Bonds and Gold Reveal MongoDB Affirms Outlook and Accelerates Stock Price Reversal Are NVIDIA's Ethernet Wins Signs of Hope or Horror for Arista? AT&T: Is This Telecom Giant a Buy or a Bye for Your Portfolio? Why Visa's Innovation Engine Keeps It a Top Portfolio Pick Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
